INDIA – Lord’s Mark Industries is expanding its presence in India’s healthcare market with a new subsidiary called Lord’s Mark Microbiotech.
The new wholly-owned subsidiary, Lord’s Mark Microbiotech, will offer preventive genome testing services in India.
Lord’s Mark Microbiotech will focus on preventive genomic testing for early detection, screening, and personalised interventions for diseases such as cancer, cardiovascular disorders, diabetes, and/or hereditary conditions.
The new subsidiary also will work closely with leading scientific and research institutes to develop and deploy diagnostic tools for various diseases.
In a press release, Lord’s Mark Industries said: “Through the company’s website, people can order genome testing kits online. The kits will be delivered within 48 hours and reverse pick up after the test is conducted as well.”
Lord’s Mark Industries disclosed that the price range for the genome testing kits developed by Lord’s Mark Microbiotech will range between Rs. 8000 (approximately US$97) to Rs.16,000 (approx. US$194).
The genome testing kits developed by Lord’s Mark Microbiotech are projected to provide an end-to-end preventive genetic testing solution.
As part of this new arrangement, Lord’s Mark Industries has opened the first laboratory owned by Lord’s Mark Microbiotech.
Lord’s Mark Industries is carving out its genome testing business as a wholly owned subsidiary amid the growing demand for genetic testing companies over the years.
Moreover, Lord’s Mark Microbiotech will be responsible for offering accessible and affordable genome testing services in multiple locations across India, including 48 cities nationwide.
“The initial focus of the new subsidiary will be on metro and Tier 1 cities, then Tier 2 cities and eventually, Tier 3 towns over the next 3-4 years,” announced Lord’s Mark Industries.
The Indian-based subsidiary has significant potential to unlock new opportunities to revolutionise healthcare in India.
With the advent of Lord’s Mark Microbiotech, Lord’s Mark Industries plans to introduce saliva-based technology for genome testing through its brand MyDNA, which results in 99% accuracy.
The diversified group is set to introduce its saliva-based technology for genome testing that does not require the extraction of blood or a phlebotomist.
According to Lord’s Mark Industries, its soon-to-be-launched product is a saliva-based that can be used at home or in a private location. An individual can do it after reading the enclosed instructions in the kit at their home.
The company further said that Lord’s Mark Microbiotech will be responsible for producing products and technology for genetic testing.
“Lord’s Mark Microbiotech will aim to make the products and technology for genome tests available to the common people nationwide through doctors and healthcare providers,” stated Lord’s Mark Industries.
In another development, Lord’s Mark Industries has its patented algorithm called SNAPPY for calculating the Polygenic Risk Score (PRS).
A polygenic risk score uses genomic information alone to assess a person’s chances of having or developing a particular medical condition.
According to the National Human Genome Research Institute (NHGRI), a polygenic risk score can only explain the relative risk for a disease.
A polygenic risk score is one way by which people can learn about their risk of developing a disease, based on the total number of changes related to the disease.
“Our patented algorithm for calculating the Polygenic Risk Score estimates an individual’s genetic risk (predisposition) for a trait or condition. PRS takes the sum (aggregate) of all known common variants to calculate an overall genetic risk for a particular disease,” stated Lord’s Mark Industries.
What’s more, the launch of the new subsidiary, Lord’s Mark Microbiotech, coincides with the completion of 25 years of excellence in business by Lord’s Mark Industries.
Lord’s Mark Microbiotech is expected to make an initial investment of INR 20 crore (US$2,421,336) to generate revenue of INR 100 crore (US$12,106,680) in 5 years.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
